VTR vs SBRA

For growth investors, Ventas, Inc.

(VTR) is the stronger pick with 18. 5% revenue growth year-over-year, versus 10. 2% for Sabra Health Care REIT, Inc. (SBRA). Sabra Health Care REIT, Inc. (SBRA) offers the better valuation at 31. 8x trailing P/E (29. 5x forward), making it the more compelling value choice. Analysts rate Ventas, Inc. (VTR) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sabra Health Care REIT, Inc.

(SBRA) is the cheapest at 31. 8x versus Ventas, Inc. at 160. 7x. On forward P/E, Sabra Health Care REIT, Inc. is actually cheaper at 29. 5x.

Over the past 5 years, Ventas, Inc.

(VTR) delivered a total return of +80. 0%, compared to +53. 4% for Sabra Health Care REIT, Inc. (SBRA). Over 10 years, the gap is even starker: VTR returned +67. 4% versus SBRA's +54. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sabra Health Care REIT, Inc.

(SBRA) is the lower-risk stock at -0. 06β versus Ventas, Inc. 's 0. 01β — meaning VTR is approximately -115% more volatile than SBRA relative to the S&P 500. On balance sheet safety, Sabra Health Care REIT, Inc. (SBRA) carries a lower debt/equity ratio of 90% versus 105% for Ventas, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ventas, Inc.

(VTR) is pulling ahead at 18. 5% versus 10. 2% for Sabra Health Care REIT, Inc. (SBRA). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to 18. 5% for Sabra Health Care REIT, Inc.. Over a 3-year CAGR, VTR leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Sabra Health Care REIT, Inc.

(SBRA) is the more profitable company, earning 20. 1% net margin versus 4. 3% for Ventas, Inc. — meaning it keeps 20. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBRA leads at 34. 1% versus 14. 2% for VTR. At the gross margin level — before operating expenses — SBRA leads at 65. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sabra Health Care REIT, Inc.

(SBRA) trades at 29. 5x forward P/E versus 118. 3x for Ventas, Inc. — 88. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VTR: 4. 6% to $90. 80.

All stocks in this comparison pay dividends.

Sabra Health Care REIT, Inc. (SBRA) offers the highest yield at 5. 8%, versus 2. 1% for Ventas, Inc. (VTR).

For long-horizon retirement investors, Sabra Health Care REIT, Inc.

(SBRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 06), 5. 8% yield). Both have compounded well over 10 years (SBRA: +54. 1%, VTR: +67. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VTR is a mid-cap high-growth stock; SBRA is a small-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.